AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/lqGVHKw3XF https://t.co/EyLuf8QLZA
Links:
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in P…
https://buff.ly/447pUrf
Apr-18-2024
